Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.74 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27085094 | 0.85 | HTR6 (1.00) | HTR6HTR2AMTNR1AMTNR1BCYP2D6 | |
| SCHEMBL30630326 | 0.85 | HTR6 (1.00) | HTR6HTR2AMTNR1AMTNR1BCYP2D6 | |
| SCHEMBL23707172 | 0.82 | HTR2A (0.69) | HTR6HTR2AMTNR1AMTNR1BKDM4E | |
| SCHEMBL24328225 | 0.81 | HTR2A (0.68) | HTR6HTR2AMTNR1AMTNR1BKDM4E | |
| SCHEMBL10688869 | 0.80 | HTR6 (0.50) | HTR6HTR2AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL2379736 | 0.80 | TRPM8 (0.67) | HTR6HTR2AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL1399180 | 0.80 | LMNA (0.53) | HTR6HTR2AALDH1A1LMNAMAPT | |
| SCHEMBL24243676 | 0.80 | HTR6 (0.80) | HTR6HTR2AMTNR1AMTNR1BKDM4E | |
| SCHEMBL31415131 | 0.79 | HTR2A (0.61) | HTR6HTR2AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL11494193 | 0.79 | HTR2A (0.61) | HTR6HTR2AKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | University of Florida Research Foundation, Incorporation (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | University of Florida Research Foundation, Incorporation (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | University of Florida Research Foundation, Incorporation (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2022055922-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | EXPANSION THERAPEUTICS, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| EP-3307724-B1 | (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES | NAT UNIV SINGAPORE (SG) | 2020-06-10 | — | — | EP | disclosed |
| EP-3307724-B1 | (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES | NAT UNIV SINGAPORE (SG) | 2020-06-10 | — | — | EP | disclosed |
| US-10308631-B2 | Selective anti-cancer compounds | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2019-06-04 | — | — | US | disclosed |
| US-10308631-B2 | Selective anti-cancer compounds | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2019-06-04 | — | — | US | disclosed |
| US-20180179178-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2018-06-28 | — | — | US | disclosed |
| US-20180179178-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2018-06-28 | — | — | US | disclosed |
| EP-2384753-B1 | Hydantoin derivatives as inhibitors of cellular necrosis | BRIGHAM & WOMENS HOSPITAL (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8741942-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-03 | — | — | US | disclosed |
| US-20120149702-A1 | INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8143300-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2384753-A1 | Hydantoin derivatives as inhibitors of cellular necrosis | The Brigham and Women's Hospital, Inc. (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20110144169-A1 | Inhibitors of cellular necrosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-06-16 | — | — | US | disclosed |
| US-7491743-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1663184-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005077344-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050119260-A1 | Inhibitors of cellular necrosis | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308631-B2 | Selective anti-cancer compounds | CCNA1, CCNY, CCNT1 | HTR6 4172/4885HTR2A 4698/4885MTNR1A 2983/4885 |
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | FUS, SNRPE, RRBP1 | HTR6 2485/4885HTR2A 3031/4885MTNR1A 3023/4885 |
| US-20050119260-A1 | Inhibitors of cellular necrosis | TNF, AIFM1, BAD | HTR6 3294/4885HTR2A 4015/4885MTNR1A 1614/4885 |
| US-20180179178-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | CCNA1, CCNY, CCNT1 | HTR6 4172/4885HTR2A 4698/4885MTNR1A 2983/4885 |
| US-20110144169-A1 | Inhibitors of cellular necrosis | TNF, AIFM1, BAD | HTR6 3294/4885HTR2A 4015/4885MTNR1A 1614/4885 |
| US-20120149702-A1 | INHIBITORS OF CELLULAR NECROSIS | TNF, AIFM1, BAD | HTR6 3294/4885HTR2A 4015/4885MTNR1A 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.